{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.41","value":"70.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.02","value":"-1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"}],"units":"Participants"}],"title":"Change at Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.62","value":"0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"}],"units":"Participants"}],"title":"Change at Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.64","value":"-0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"}],"units":"Participants"}],"title":"Change at Cycle 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.84","value":"1.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"title":"Change at Cycle 10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.49","value":"0.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"}],"units":"Participants"}],"title":"Change at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.61","value":"2.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"title":"Change at Cycle 16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.31","value":"-1.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"title":"Change at Cycle 19"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.05","value":"-8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"title":"Change at Cycle 22"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.44","value":"-4.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Change at Cycle 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.50","value":"-6.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Change at Cycle 28"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Change at Cycle 31"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Change at Cycle 34"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.30","value":"-7.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"title":"End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"}],"units":"Participants"}],"description":"EORTC QLQ-C30 is a cancer-specific instrument that contains 30 questions for evaluation of new chemotherapy \\& assessment of participant reported outcome. EORTC QLQ-C30 included global health status/quality of life (GHS/QOL), functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 are 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale \\& are 7-point scale (1/Very Poor to 7/Excellent). GHS total score is calculated as (\\[{Q29+Q30}/2\\]-1)/6\\*100. Answers are converted into grading scale, with values between 0 (worse outcome) to100 (best outcome). High score represents a favorable outcome with best quality of life for participant.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with iCCA with tumors harboring FGFR2 gene rearrangements received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG000","title":"Phase 2"}],"paramType":"MEAN","populationDescription":"Analysis was performed on PRO population. Here, 'number analyzed' = number of participants with available data for each specified category.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])","title":"Phase 2:Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status Score at Specified Timepoints","type":"SECONDARY","unitOfMeasure":"score on scale"}